Alumis' Lupus Drug Fails Mid-Stage Trial, Sending Shares Down
ALMS has more than doubled off its 52-week low of $3.76.
Summary
Alumis' oral TYK2 inhibitor envudeucitinib failed to meet the primary endpoint in a Phase 2 trial for systemic lupus erythematosus. The company announced topline results from the Phase 2b trial, confirming the drug did not meet endpoints. This is a major setback for the company's lead pipeline asset, which had shown promise in earlier studies. The failure raises doubts about the drug's viability in lupus and could impact the planned NDA submission for a different indication. Investors will likely reassess the company's valuation given the high reliance on this program. The stock is expected to react sharply to this news.
At the time of this announcement, ALMS was trading at $22.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.76 to $31.35. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.